For a good long time, economists have been thinking about the reimbursement quandary for antibiotics, esp. antibacterials. They are just too cheap, right? Well, with the exception of HCV and some newer HIV drugs, few compounds have ever reached the Continue reading The EpiPen Episode, an Epitaph on Epinephrine as we know it, an Epilogue and an Epiphany
SVR rates in recent DAA combination trials are really impressive. Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies. This Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?
It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick Continue reading 2014: The Year That Changed The Landscape of HCV Therapy